Citadel Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-342,195
| Closed | -$544K | – | 7140 |
|
|
2024
Q1 | $544K | Buy |
342,195
+270,021
| +374% | +$429K | ﹤0.01% | 3805 |
|
|
2023
Q4 | $62K | Sell |
72,174
-91,972
| -56% | -$79K | ﹤0.01% | 5047 |
|
|
2023
Q3 | $176K | Sell |
164,146
-182,344
| -53% | -$195K | ﹤0.01% | 4615 |
|
|
2023
Q2 | $897K | Buy |
346,490
+269,101
| +348% | +$697K | ﹤0.01% | 3090 |
|
|
2023
Q1 | $316K | Buy |
77,389
+50,997
| +193% | +$208K | ﹤0.01% | 4263 |
|
|
2022
Q4 | $132K | Sell |
26,392
-267,743
| -91% | -$1.34M | ﹤0.01% | 4889 |
|
|
2022
Q3 | $3.85M | Buy |
294,135
+66,414
| +29% | +$869K | ﹤0.01% | 2091 |
|
|
2022
Q2 | $2.92M | Buy |
227,721
+69,928
| +44% | +$896K | ﹤0.01% | 2376 |
|
|
2022
Q1 | $2.41M | Sell |
157,793
-536,354
| -77% | -$8.18M | ﹤0.01% | 2819 |
|
|
2021
Q4 | $12.3M | Sell |
694,147
-64,508
| -9% | -$1.14M | ﹤0.01% | 1274 |
|
|
2021
Q3 | $15.9M | Buy |
758,655
+50,576
| +7% | +$1.06M | ﹤0.01% | 1070 |
|
|
2021
Q2 | $14M | Buy |
708,079
+327,650
| +86% | +$6.46M | ﹤0.01% | 1199 |
|
|
2021
Q1 | $11.1M | Buy |
380,429
+214,036
| +129% | +$6.22M | ﹤0.01% | 1364 |
|
|
2020
Q4 | $5.04M | Buy |
166,393
+125,036
| +302% | +$3.79M | ﹤0.01% | 1762 |
|
|
2020
Q3 | $658K | Buy |
41,357
+13,404
| +48% | +$213K | ﹤0.01% | 3266 |
|
|
2020
Q2 | $551K | Sell |
27,953
-176,968
| -86% | -$3.49M | ﹤0.01% | 3380 |
|
|
2020
Q1 | $2.53M | Buy |
204,921
+167,388
| +446% | +$2.06M | ﹤0.01% | 2012 |
|
|
2019
Q4 | $694K | Buy |
37,533
+14,118
| +60% | +$261K | ﹤0.01% | 3314 |
|
|
2019
Q3 | $325K | Buy |
23,415
+3,700
| +19% | +$51.4K | ﹤0.01% | 3794 |
|
|
2019
Q2 | $289K | Buy |
+19,715
| New | +$289K | ﹤0.01% | 3892 |
|